AI
ESPR icon

Atom Investors’s Esperion Therapeutics ESPR Stock Holding History

Atom Investors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-121,722
Closed -$816K – 250
2022
Q3 		$816K Buy
+121,722
New +$836K 0.29% 115
2020
Q1 		– Sell
-7,902
Closed -$471K – 338
2019
Q4 		$471K Buy
+7,902
New +$355K 0.04% 183

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Atom Investors's ESPR Position: Q4 2022 in Review

Atom Investors sold out of Esperion Therapeutics (ESPR) in Q4 2022, closing a stake of 121,722 shares — an estimated $816K sold.

Atom Investors first reported a position in ESPR in Q4 2019 and held it in 2 quarters. The position peaked at $816K in Q3 2022. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

  • Atom Investors reported no remaining Esperion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Atom Investors sold 121,722 Esperion Therapeutics shares in Q4 2022, an estimated $816K.
  • Atom Investors first reported a position in Esperion Therapeutics in Q4 2019 and held it in 2 quarters.
  • Atom Investors's Esperion Therapeutics position peaked at $816K in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Atom Investors's 13F filing for Q4 2022, filed 14 Feb 2023.